Search for Clinical Trial Results
Bullous Pemphigoid - 28 Studies Found
Status | Study |
Completed |
Study Name: Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2007-07-20 Interventions: Drug: Mabthera Two IV perfusions of 1000mg at 15 days intervals |
Completed |
Study Name: Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Condition: Bullous Pemphigoid Date: 2008-12-11 Interventions:
|
Completed |
Study Name: Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Condition: Bullous Pemphigoid Date: 2011-07-27 Interventions:
|
Terminated |
Study Name: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Condition: Bullous Pemphigoid Date: 2012-09-17 Interventions:
|
Terminated |
Study Name: Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2014-12-08 Interventions:
|
Completed |
Study Name: Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2007-02-02 Interventions: Drug: Azathioprine or Mycophenolate mofetil |
Completed |
Study Name: Efficacy and Safety of Omalizumab in Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2007-05-08 Interventions:
|
Completed |
Study Name: Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2008-12-03 Interventions: Drug: leflunomide |
Completed |
Study Name: Rituximab in the Treatment of Patients With Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2006-02-01 Interventions: Drug: Rituximab Infusion of 1000 mg of rituximab on day 0 and day 14 |
Completed |
Study Name: Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Condition: Bullous Pemphigoid Date: 2016-08-25 Interventions: Other: Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9 |